ArticleFrontiers in endocrinology2022

HRAS overexpression predicts response to Lenvatinib treatment in gastroenteropancreatic neuroendocrine tumors.

Chiara Liverani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.